Copanlisib (Aliqopa), an inhibitor of PI3K, predominantly against the isoforms PI3Kα and PI3Kδ, was approved by the FDA in September 2017 for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies (https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-follicular-lymphoma; 14 September 2017). Here, PIK3CA is linked to follicular lymphoma.